Oncternal Therapeutics (DB:GTU) - Stock Price, News & Analysis

GTU Stock Overview

Oncternal Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica centrada en el desarrollo de terapias oncológicas para cánceres con necesidades médicas críticas no cubiertas.

About the company

GTU fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Risk Analysis

Tiene unos ingresos inferiores a 1 millón de dólares ($659K)

Las acciones son altamente ilíquidas

Se prevé que los beneficios disminuyan una media de 9.9% al año durante los próximos 3 años.

No tiene una capitalización bursátil significativa (€24M)

+ 1 more risk

Oncternal Therapeutics, Inc. Competitors

Medigene

XTRA:MDG1

€53.3m

co.don

XTRA:CNW

€6.5m

Epigenomics

XTRA:ECX

€1.6m

2invest

XTRA:2INV

€48.9m

Price History & Performance

Summary of all time highs, changes and price drops for Oncternal Therapeutics
Historical stock prices
Current Share Price	US$5.32
52 Week High	US$11.80
52 Week Low	US$4.04
Beta	1.37
1 Month Change	0%
3 Month Change	-38.71%
1 Year Change	17.70%
3 Year Change	-96.95%
5 Year Change	n/a
Change since IPO	-94.78%

Recent updates

Shareholder Returns

	GTU	DE Biotechs	DE Market
7D	0%	4.5%	-1.3%
1Y	17.7%	-13.9%	4.1%

Rentabilidad frente al sector: GTU obtuvo unos resultados inferiores a los del sector German Biotechs , que el año pasado arrojó un rendimiento del -23.6%.

Rentabilidad vs. Mercado: GTU superó al mercado German, que obtuvo un rendimiento del 5.4% el año pasado.

Price Volatility

Is GTU's price volatile compared to industry and market?
GTU volatility
GTU Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.0%
Market Average Movement	4.7%
10% most volatile stocks in DE Market	9.7%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: GTUha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de GTU en el último año.

About the Company

Founded	Employees	CEO	Website
n/a	29	Jim Breitmeyer	https://www.oncternal.com

Oncternal Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica centrada en el desarrollo de terapias oncológicas para cánceres con necesidades médicas críticas no cubiertas. La cartera de productos clínicos de la empresa incluye zilovertamab, un anticuerpo monoclonal humanizado que se une al receptor huérfano 1 similar a la tirosina quinasa (ROR1), y ONCT-216, una pequeña molécula que inhibe la actividad biológica de las oncoproteínas del factor de transcripción de la familia ETS, que se encuentra en un ensayo clínico de fase 1/2. También está desarrollando ONCT-808, un fármaco que inhibe la actividad de las oncoproteínas del factor de transcripción de la familia ETS.

Oncternal Therapeutics, Inc. Fundamentals Summary

How do Oncternal Therapeutics's earnings and revenue compare to its market cap?
GTU fundamental statistics
Market cap	€23.13m
Earnings (TTM)	-€36.63m
Revenue (TTM)	€728.40k

31.8x

P/S Ratio

-0.6x

P/E Ratio

Is GTU overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GTU income statement (TTM)
Revenue	US$785.00k
Cost of Revenue	US$29.75m
Gross Profit	-US$28.97m
Other Expenses	US$10.51m
Earnings	-US$39.48m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-14.68
Gross Margin	-3,690.19%
Net Profit Margin	-5,029.17%
Debt/Equity Ratio	0%

How did GTU perform over the long term?

See historical performance and comparison

GTU Stock Overview

Rewards

Risk Analysis

Oncternal Therapeutics, Inc. Competitors

XTRA:MDG1

€53.3m

XTRA:CNW

€6.5m

XTRA:ECX

€1.6m

XTRA:2INV

€48.9m

Price History & Performance

Recent News & Updates

Oncternal Therapeutics, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science

Oncternal Therapeutics, Inc. Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics Announces Reverse Stock Split to Bring the Company into Compliance with Nasdaq’s Minimum Bid Price Requirement

Oncternal Therapeutics, Inc. Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma

Third quarter 2023 earnings released: US$0.17 loss per share (vs US$0.20 loss in 3Q 2022)

Recent updates

Oncternal Therapeutics, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science

Oncternal Therapeutics, Inc. Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics Announces Reverse Stock Split to Bring the Company into Compliance with Nasdaq’s Minimum Bid Price Requirement

Oncternal Therapeutics, Inc. Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma

Third quarter 2023 earnings released: US$0.17 loss per share (vs US$0.20 loss in 3Q 2022)

Oncternal Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics, Inc. Adds Matthew Smith to its Prostate Cancer Scientific Advisory Board

New major risk - Financial position

Nasdaq Grants Oncternal Therapeutics an Additional 180 Calendar Days, or to April 1, 2024, to Regain Compliance with the Minimum Bid Requirement

Nasdaq Grants Oncternal Therapeutics an Additional 180 Calendar Days, or to April 1, 2024, to Regain Compliance with the Minimum Bid Requirement

Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.23 loss in 2Q 2022)

Oncternal Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Oncternal Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Study of ROR1 Targeting Autologous CAR T, ONCT-808, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma

Oncternal Therapeutics, Inc., Annual General Meeting, Jun 28, 2023

First quarter 2023 earnings released: US$0.20 loss per share (vs US$0.20 loss in 1Q 2022)

Full year 2022 earnings released: US$0.84 loss per share (vs US$0.64 loss in FY 2021)

Oncternal Therapeutics, Inc. Appoints Jill DeSimone to the Board of Directors

Oncternal Therapeutics, Inc. Announces the Resignation of Jinzhu Chen from the Board of Directors

Oncternal Therapeutics, Inc. Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib

Third quarter 2022 earnings released: US$0.20 loss per share (vs US$0.20 loss in 3Q 2021)

Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022

Oncternal Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Oncternal Therapeutics Receives IND Clearance for ONCT-808, Its Autologous Car T Product Candidate Targeting Ror1 for the Treatment of Aggressive B Cell Lymphoma

Oncternal Therapeutics, Inc Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL

Oncternal Therapeutics, Inc. Submitted an Investigational New Drug Application (“IND”) for ONCT-808

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.16 loss in 2Q 2021)

Oncternal Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

High number of new directors

Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in Combination with Ibrutinib for Patients with MCL

Oncternal Therapeutics, Inc. Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress

Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib At Asco 2022

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.12 loss in 1Q 2021)

Oncternal Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

High number of new and inexperienced directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Oncternal Therapeutics, Inc. Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma

Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib At ASH 2021

Third quarter 2021 earnings released: US$0.20 loss per share (vs US$0.22 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.34 loss in 2Q 2020)

Independent Director Man Cho has left the company

Oncternal Therapeutics Presents Updated Interim Data for Cirmtuzumab in Combination with Ibrutinib At ASCO 2021

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.31 loss in 1Q 2020)

New 90-day high: €6.95

Revenue beats expectations

Full year 2020 earnings released: US$0.85 loss per share (vs US$3.31 loss in FY 2019)

Oncternal Therapeutics, Inc. to Report Q4, 2020 Results on Mar 11, 2021

New 90-day high: €5.45

Oncternal Therapeutics, Inc. Appoints Rosemary Mazanet as a Class I Director

Oncternal Therapeutics, Inc.(NasdaqCM:ONCT) dropped from Russell 2000 Dynamic Index

Oncternal Therapeutics, Inc. and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell Therapies

Oncternal Therapeutics, Inc. Announces Updated Interim Clinical Data from the Ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib Targeting ROR1 for Leukemia and Lymphoma) Clinical Trial

Oncternal Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $22.500002 million.

Oncternal Therapeutics, Inc. Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2020 Virtual Annual Meeting

New 90-day high: €2.90

Third quarter 2020 earnings released: US$0.22 loss per share